Research Updates

New studies continue to shed light on ADHD in adults, highlighting increasing diagnosis rates and shifting treatment paradigms. A recent nationwide study from Finland found that adults with ADHD tend to reduce their use of antidepressants after starting ADHD-specific treatment, underscoring the importance of accurate diagnosis and tailored therapy. Another major finding is the recognition […]

New studies continue to shed light on ADHD in adults, highlighting increasing diagnosis rates and shifting treatment paradigms. A recent nationwide study from Finland found that adults with ADHD tend to reduce their use of antidepressants after starting ADHD-specific treatment, underscoring the importance of accurate diagnosis and tailored therapy. Another major finding is the recognition

2025 is proving to be a breakthrough year for ADHD treatment innovation. New ADHD medications, including novel non-stimulants and advanced delivery systems, are nearing approval to offer more effective symptom control with fewer side effects. For instance, drugs like Azstarys, which combines dexmethylphenidate with a prodrug for smoother delivery, and Qelbree (viloxazine), a non-stimulant effective